대한안과학회지 (Journal of The Korean Ophthalmological Society)

  • 제59권11호
  • /
  • Pages.1030-1038
  • /
  • 2018
  • /
  • 0378-6471(pISSN)
  • /
  • 2092-9374(eISSN)
대한안과학회 (The Korean Ophthalmological Society)
권호 표지
DOI QR코드

DOI QR Code

신생혈관 연령관련황반변성에서 항혈관내피세포성장인자 주입술 시행 후 시력 반응의 의의

Significance of Early Visual Responses to Anti-Vascular Endothelial Growth Factor in Age-related Macular Degeneration

  • Song, Hee Jun (Department of Ophthalmology, Myongji Hospital) ;
  • Yang, Ji Ho (Department of Ophthalmology, Myongji Hospital) ;
  • Kim, Do Gyun (Department of Ophthalmology, Myongji Hospital)
  • 투고 : 2018.07.12
  • 심사 : 2018.10.22
  • 발행 : 2018.11.15
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 신생혈관 연령관련황반변성 환자에서 유리체강 내 항혈관내피세포성장인자 주입술 1회 시행 후 1개월째 시력 반응의 정도 및 3회 시행 후 1개월째 시력 반응의 정도와 치료 시작 12개월 후의 시력과의 상관관계를 알아보고자 하였다. 대상과 방법: 신생혈관 연령관련황반변성으로 진단받은 환자들 중 유리체강 내 항혈관내피세포성장인자 주입술로 치료하면서 12개월 이상 경과관찰이 가능했던 환자 30명의 의무기록을 분석하였다. 유리체강 내 주입술 1회 시행 후 1개월째 최대교정시력을 측정하였고 3회 주입술 후 1개월째 최대교정시력을 측정하여 상승 정도(<1, 1-<3, ${\geq}3$줄; logMAR)에 따른 치료 시작 후 12개월째 최대교정시력과 비교하였다. 결과: 첫 주사 후 1개월째 1줄 미만의 시력 향상을 보인 군은 6안(20%), 1줄 이상 3줄 미만의 시력 향상을 보인 군은 7안(23.3%), 3줄 이상 시력 향상을 보인 군은 17안(56.6%)이었다. 세 번째 주사 후 1개월째 1줄 미만의 시력 향상을 보인 군은 9안(30%), 1줄 이상 3줄 미만의 시력 향상을 보인 군은 9안(30%), 3줄 이상의 시력 향상을 보인 군은 12안(40%)이었다. 로지스틱 회귀 분석 및 선형회귀분석에서 3회 주입술 후 1개월째의 3줄 이상의 시력 향상은 치료 시작 12개월 후의 3줄 이상의 시력상승과 유의한 상관관계를 보였다(p=0.04). 결론: 신생혈관 연령관련황반변성 환자에서 유리체강 내 주입술 3회 시행 후 1개월째 3줄 이상의 시력 향상 여부는 치료 시작 12개월 후의 3줄 이상의 시력예후와 통계적으로 유의한 상관관계를 보였다.

Purpose: To evaluate whether early visual acuity response at 4 weeks after the first intravitreal anti-vascular endothelial growth factor (VEGF) injection or 4 weeks after the third injection in neovascular age-related macular degeneration (nAMD) is associated with 12-month follow-up outcome. Methods: Thirty treatment-naive patients (30 eyes) with nAMD, treated with intravitreal anti-VEGF, were retrospectively included. Initially, all patients were injected at least three times for three consecutive months and followed up with a pro re nata regimen for at least 12 months. The relationship between 4 weeks after the first and third anti-VEGF injections in visual acuity response was explored, including the mean change from baseline in best-corrected visual acuity (BCVA). The mean change in BCVA was classified into three groups according to visual improvement: <1, 1-<3, or ${\geq}3$ logMAR line(s) in BCVA. The associations among baseline characteristics (gender, age, duration of symptoms, initial BCVA, central macular thickness, and intraocular pressure) and visual acuity responses 4 weeks after the first and third anti-VEGF injections were also assessed. Results: The proportions of eyes with <1, 1-<3, and ${\geq}3-line(s)$ improvement at 4 weeks after the first injection were 6 eyes (20%), 7 eyes (23.3%), and 17 eyes (56.6%), respectively. The proportions of eyes with <1, 1-<3, and ${\geq}3-line(s)$ improvement at 4 weeks after the third injection were 9 eyes (30%), 9 eyes (30%), and 12 eyes (40%), respectively. A BCVA response ${\geq}3-lines$ improvement at 4 weeks after the third injection showed significant associations with ${\geq}3-line(s)$ improvement and BCVA response at 12 months in multiple logistic and linear regression analyses (p = 0.04). Conclusions: In this study, BCVA response ${\geq}3-lines$ improvement at 4 weeks after the third injection showed a significant association with ${\geq}3-line(s)$ improvement and BCVA response at 12 months.

키워드

참고문헌

  1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72. https://doi.org/10.1001/archopht.122.4.564
  2. Au Eong KG. Age-related macular degeneration: an emerging challenge for eye care and public health professionals in the Asia Pacific region. Ann Acad Med Singapore 2006;35:133-5.
  3. Park SJ, Lee JH, Woo SJ, et al. Age-related macular degeneration: prevalence and risk factors from Korean National Health and Nutrition Examination Survey, 2008 through 2011. Ophthalmology 2014;121:1756-65. https://doi.org/10.1016/j.ophtha.2014.03.022
  4. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8. https://doi.org/10.1073/pnas.172398299
  5. Brechner RJ, Rosenfeld PI, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. Am J Ophthalmol 2011;151:887-95.e1. https://doi.org/10.1016/j.ajo.2010.11.017
  6. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. https://doi.org/10.1056/NEJMoa062655
  7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. https://doi.org/10.1056/NEJMoa054481
  8. Heier JS, Brown DM. Chong V, et al. Intravitreal aflibercept (VEGF trap-Eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48. https://doi.org/10.1016/j.ophtha.2012.09.006
  9. Ying GS, Maguire MG, Daniel E, et al. Association of baseline characteristics and early vision response with 2-year vision outcomes in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 2015;122:2523-31.e1. https://doi.org/10.1016/j.ophtha.2015.08.015
  10. Sagiv O, Zloto O, Moroz I, Moisseiev J. Different clinical courses on long-term follow-up of age-related macular degeneration patients treated with intravitreal anti-vascular endothelial growth factor injections. Ophthalmologica 2017;238:217-25. https://doi.org/10.1159/000479437
  11. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991;109:1232-41. https://doi.org/10.1001/archopht.1991.01080090056026
  12. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-9. https://doi.org/10.1001/archopht.1993.01090090052019
  13. Zhang X, Lai TYY. Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int 2018;2018:9640131.
  14. Lee HW, Kim HC. Correlation between visual outcomes and pre-treatment factors including hyperreflective foci in neovascular age-related macular degeneration. J Korean Ophthalmol Soc 2015;56:1188-94. https://doi.org/10.3341/jkos.2015.56.8.1188
  15. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20. https://doi.org/10.1136/bjo.2011.204685
  16. Ehlken C, Jungmann S, Bohringer D, et al. Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD. Eye (Lond) 2014;28:538-45. https://doi.org/10.1038/eye.2014.64
  17. Kaiser PK; Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, et al. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2009;116:747-55. https://doi.org/10.1016/j.ophtha.2008.12.057
  18. Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012;119:1001-10. https://doi.org/10.1016/j.ophtha.2012.02.003
  19. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119:992-1000. https://doi.org/10.1016/j.ophtha.2012.02.002
  20. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371-6. https://doi.org/10.1167/iovs.05-0354
  21. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007;85:486-94. https://doi.org/10.1111/j.1755-3768.2007.00979.x